Deutsche Bank initiated coverage of Autolus Therapeutics with a Buy rating and $10 price target. Feedback the firm has collected from oncologists suggests that Autolus’ obe-cel will “largely become the CD19 CAR-T of choice” for adults with relapsed/refractory B-cell Acute Lymphoblastic Leukemia, or B-ALL, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AUTL: